Jove
Visualize
Contact Us

Related Concept Videos

Stimulants01:29

Stimulants

Stimulants are substances that enhance neural activity and elevate dopamine levels in the brain, leading to their highly addictive nature. These drugs include cocaine, amphetamines, MDMA, caffeine, and nicotine, each with distinct mechanisms of action and varied health implications.
Cocaine can be administered via snorting, injection, or smoking. It primarily functions by blocking the reuptake of dopamine, resulting in a euphoric high characterized by an intense sensation of happiness and...
Adrenergic Agonists: Mixed-Action Agents01:28

Adrenergic Agonists: Mixed-Action Agents

Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...
Drug Abuse and Addiction: Pharmacological Phenomena01:15

Drug Abuse and Addiction: Pharmacological Phenomena

Drug dependence, abuse, and addiction are complex phenomena that can precipitate various abnormal states. Physical dependence refers to a state of pharmacological adaptation to a drug. This adaptation often results in tolerance—a reduced response to the drug after repeated administrations. When the drug use is abruptly stopped, withdrawal symptoms occur due to the body's need to readjust from the pharmacologically induced imbalance. However, tolerance and withdrawal symptoms do not necessarily...
CNS Stimulants: Cocaine, Amphetamines and Cannabinoids01:24

CNS Stimulants: Cocaine, Amphetamines and Cannabinoids

CNS stimulants, such as cocaine, amphetamines, and cannabinoids, have varying structures and mechanisms of action that lead to different therapeutic effects and side effects. Cocaine, with its molecular formula C17H21NO4, is a tropane alkaloid and a tertiary amino compound. It has two chemical forms: the hydrochloride salt and the "freebase." The former is in powder form, while the latter involves removing the hydrochloride salt to create a form that can be smoked. Cocaine exerts its effects by...
Adrenergic Neurons: Neurotransmission01:27

Adrenergic Neurons: Neurotransmission

Postganglionic sympathetic fibers (except those supplying the sweat glands) releasing noradrenaline or norepinephrine are called noradrenergic or adrenergic neurons. Noradrenaline, dopamine, adrenaline, or epinephrine are collectively called "catecholamines" as they contain a catechol moiety and an amine side chain. The five stages of neurotransmitter release involve their synthesis, storage, release, reuptake and metabolism.
Synthesis: Catecholamine synthesis requires tyrosine, which is taken...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Recent cannabis exposure and acute nicotine effects: insights from randomized, double-blind, placebo-controlled intravenous nicotine studies.

The international journal of neuropsychopharmacology·2026
Same author

An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Neuroimaging as the 'missing link' for preclinical to clinical translation: an example using N-acetylcysteine among individuals with cocaine- and opioid-use disorders receiving methadone treatment.

Psychopharmacology·2026
Same author

Addressing tobacco use in the context of opioid use disorder: A systematic review of smoking cessation interventions.

The American journal on addictions·2026
Same author

Cannabis Co-Use and Endocannabinoid System Modulation in Tobacco Use Disorder: A Translational Systematic Review and Meta-Analysis.

medRxiv : the preprint server for health sciences·2026
Same author

Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study.

Addictive behaviors reports·2026
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 30, 2026

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

Norepinephrine and stimulant addiction.

Mehmet Sofuoglu1, R Andrew Sewell

  • 1Department of Psychiatry, School of Medicine, Yale University, USA and VA Connecticut Healthcare System, USA. mehmet.sofuoglu@yale.edu

Addiction Biology
|September 25, 2008
PubMed
Summary
This summary is machine-generated.

Currently, no medications are approved for stimulant use disorders. This research explores the role of norepinephrine (NE) in stimulant addiction, suggesting NE-targeting drugs could be a promising treatment avenue.

More Related Videos

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

Comprehensive Analysis of Transcription Dynamics from Brain Samples Following Behavioral Experience
08:14

Comprehensive Analysis of Transcription Dynamics from Brain Samples Following Behavioral Experience

Published on: August 26, 2014

Related Experiment Videos

Last Updated: Jun 30, 2026

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder
07:51

A Protocol for Measuring Cue Reactivity in a Rat Model of Cocaine Use Disorder

Published on: June 18, 2018

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry
07:30

Single Cell Measurement of Dopamine Release with Simultaneous Voltage-clamp and Amperometry

Published on: November 21, 2012

Comprehensive Analysis of Transcription Dynamics from Brain Samples Following Behavioral Experience
08:14

Comprehensive Analysis of Transcription Dynamics from Brain Samples Following Behavioral Experience

Published on: August 26, 2014

Area of Science:

  • Neuroscience
  • Pharmacology
  • Addiction Medicine

Background:

  • Stimulant use disorders represent a significant public health challenge with no approved pharmacotherapies.
  • Stimulants primarily affect monoamine neurotransmitters, including dopamine (DA) and norepinephrine (NE).
  • While dopamine is key to reward, NE plays a critical role in arousal, attention, learning, and stress response, and is implicated in addiction models.

Purpose of the Study:

  • To review the role of the noradrenergic system in stimulant addiction.
  • To evaluate the potential of noradrenergic medications as therapeutic agents for stimulant use disorders.

Main Methods:

  • Review of pre-clinical models demonstrating NE's involvement in stimulant effects like sensitization and drug seeking.
  • Analysis of clinical studies investigating adrenergic blockers, NE synthesis inhibitors, alpha(2)-adrenergic agonists, and NE transporter inhibitors for treating cocaine and amphetamine use.

Main Results:

  • Pre-clinical studies show NE is crucial for mediating stimulant-induced behaviors.
  • Clinical trials indicate that disulfiram (blocking NE synthesis) increases negative cocaine urine tests.
  • Lofexidine (alpha(2)-adrenergic agonist) reduces craving, and atomoxetine (NET inhibitor) attenuates stimulant effects in humans.

Conclusions:

  • The noradrenergic system is a critical target for treating stimulant use disorders.
  • Adrenergic blockers and other NE-modulating agents show promise in clinical and pre-clinical studies.
  • Further research into noradrenergic medications is warranted for stimulant addiction treatment.